期刊
WORLD NEUROSURGERY
卷 73, 期 5, 页码 500-507出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.wneu.2010.02.026
关键词
Erythropoietin; Neuroprotection; Subarachnoid hemorrhage; Vasospasm
OBJECTIVE: Subarachnoid hemorrhage (SAH) has a worldwide incidence of approximately 10.5 cases per 100,000 person-years and constitutes 3% of all strokes. Erythropoietin (EPO) has recently been proposed for the treatment of a variety of brain diseases, including SAH, because of its neuroprotective effects. Hence, the current evidence in the published literature was reviewed to determine the potential utility of EPO in the treatment of SAH. METHODS: A careful retrospective review of the literature was performed to determine the potential benefit of employing EPO in the treatment of SAH and its sequelae. RESULTS: Careful literature review revelaed that the use of EPO may not necessarily reduce the incidence of vasospasm after SAH, but it may reduce the severity and its eventual outcome. CONCLUSION: Given the recent trial results, a dose-escalation study and subsequent randomized trial should be considered.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据